This trial is evaluating whether HZN-825 will improve 1 primary outcome and 7 secondary outcomes in patients with Usual Interstitial Pneumonia. Measurement will happen over the course of Baseline to Week 52.
This trial requires 360 total participants across 3 different treatment groups
This trial involves 3 different treatments. HZN-825 is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"The exact mechanisms of causation are not known. Possible causes include inhalation of dust or other particulates. Exposure to tobacco is also a leading cause. In addition, certain factors such as pulmonary malignancy, certain drugs and autoimmune disorders of the lungs are also believed to increase the risk of developing pulmonary fibrosis, especially pulmonary fibrosis secondary to autoimmune bronchopulmonary aspergillosis (ABPA).\n" - Anonymous Online Contributor
"In the US population with pulmonary fibrosis, between 2-5% are reported to have a family history of the disease, 3–7% have had a first degree relative with pulmonary fibrosis, and 4% have never received an occupational diagnosis of the disease. The percentage of people with pulmonary fibrosis is anticipated to increase over time." - Anonymous Online Contributor
"Results from a recent paper suggest the presence of fibrosis in patients with interstitial lung disease whose disease is clinically indistinguishable from those with idiopathic pulmonary fibrosis; the latter should be included in the differential of this disease." - Anonymous Online Contributor
"Most patients with [idiopathic pulmonary fibrosis](https://www.withpower.com/clinical-trials/idiopathic-pulmonary-fibrosis) receive no specific treatment. They are generally treated only with antibiotics and/or steroid medication if they do not improve after 3 months. Since the disease progresses slowly, even in cases of optimal treatment, patients with idiopathic pulmonary fibrosis usually live an active life long and they will have to live with a chronic disease. In some cases, the disease may be a sign of the underlying cause, so if the cause is known and treated adequately, the disease responds and is cured. In some rare cases of pulmonary fibrosis, a successful transplant of lung tissue with a functioning lung can be done, which will lead to improvement in the quality of life of the patient." - Anonymous Online Contributor
"Pulmonary fibrosis occurs when the scarring caused by the abnormal remodeling of alveoli in the lungs affects air ventilation and breathing capabilities. It is a disease of the lung that causes abnormal scarring leading to progressive loss of lung function. There are many subtypes of pulmonary fibrosis, most of which are idiopathic. It is considered a type of chronic interstitial lung disease." - Anonymous Online Contributor
"In all four subjects, lung fibrosis was resolved after the discontinuation of steroids. Thus, this form of fibrosis may be treated, in part, by discontinuing the steroid. Further, steroids may be needed to prevent progression of the other types of fibrosis." - Anonymous Online Contributor
"Hzn-825 is a novel anti-inflammatory, immunosuppressive drug. It exerts its effect through the suppression of both Th1 and Th17 cells and is thus effective in several indications, in particular SLE." - Anonymous Online Contributor
"Data from a recent study indicate that Hzn-825 may be a promising molecule of drug candidates for the treatment of lung diseases and the management of chronic pulmonary inflammatory diseases." - Anonymous Online Contributor
"Hzn-825 is not efficacious in patients with chronic interstitial lung disease; the results of the present trial do not support the use of Hzn-825 in patients with this devastating disease. The clinical trials of Hzn do not appear to be sufficiently powered in chronic interstitial lung disease or to be designed properly." - Anonymous Online Contributor
"The occurrence of PF in relatives of the same sex, with or without the simultaneous development of lung disease raises questions on whether genetic predisposition is involved in the etiology of the lung disease and on the possibility of a common environmental factor that accounts for the development of PF and lung disease in a consanguineous environment." - Anonymous Online Contributor
"The current development of the most attractive Zn-dithiophosphate compounds, such as Zn-DTP, Zn-DTPA and zinc-DNP, do not offer a satisfactory option as a therapeutic agent against ILD." - Anonymous Online Contributor
"There is variation among age groups in the percentage of pulmonary fibrosis that occurs in a population. There are some gender differences in the susceptibility to pulmonary fibrosis in certain age groups but not others. The risk of pulmonary fibrosis appears to increase with age, and, by the age of 50 years, nearly half of the cohort of Caucasian men and 2/3 of Caucasian women has pulmonary fibrosis." - Anonymous Online Contributor